Patents by Inventor Donna Gutterman

Donna Gutterman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20260083758
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: November 28, 2025
    Publication date: March 26, 2026
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • Treatment of fragile x syndrome with cannabidiol
    Patent number: 12582664
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD). Specifically, subjects having moderate to severe ASD and relatively high social avoidance and/or anxiety are more likely to show a reduction in irritability when treated with CBD.
    Type: Grant
    Filed: October 20, 2022
    Date of Patent: March 24, 2026
    Assignee: Harmony Biosciences Management, Inc.
    Inventors: Joseph Palumbo, Stephen V. O'Quinn, Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
    Publication number: 20260076984
    Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
    Type: Application
    Filed: November 24, 2025
    Publication date: March 19, 2026
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, Donna Gutterman, John Messesnheimer
  • TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL
    Publication number: 20260034151
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: October 10, 2025
    Publication date: February 5, 2026
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri B. Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
  • Treatment of behavioral impairment in developmental and epileptic encephalopathy
    Patent number: 12508270
    Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 30, 2025
    Assignee: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, Donna Gutterman, John Messenheimer
  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20250339450
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: July 11, 2025
    Publication date: November 6, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
    Publication number: 20250302734
    Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
    Type: Application
    Filed: January 28, 2025
    Publication date: October 2, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
  • TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL
    Publication number: 20250288539
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: May 30, 2025
    Publication date: September 18, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri B. Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
  • METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
    Publication number: 20250268843
    Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.
    Type: Application
    Filed: January 1, 2025
    Publication date: August 28, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw, Ted Smith, James Griesser
  • SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
    Publication number: 20250213465
    Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
    Type: Application
    Filed: July 5, 2024
    Publication date: July 3, 2025
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20250205174
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.
    Type: Application
    Filed: December 5, 2024
    Publication date: June 26, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20250195451
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: February 28, 2025
    Publication date: June 19, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20250177322
    Abstract: The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
    Type: Application
    Filed: February 6, 2025
    Publication date: June 5, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree, James Griesser, Thomas W. Dobbins
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20250134833
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: January 6, 2025
    Publication date: May 1, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20250134832
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: January 2, 2025
    Publication date: May 1, 2025
    Applicant: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 12226373
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: February 18, 2025
    Assignee: Harmony Biosciences Management, inc.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of autism with cannabidiol
    Patent number: 12213951
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Grant
    Filed: March 21, 2023
    Date of Patent: February 4, 2025
    Assignee: Harmony Biosciences Management, Inc.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of 22Q11.2 deletion syndrome with cannabidiol
    Patent number: 12186282
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: January 7, 2025
    Assignee: HARMONY BIOSCIENCES MANAGEMENT, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF SLEEP APNEA WITH CBD
    Publication number: 20240307418
    Abstract: Provided are methods of treating sleep disorders in patients by transdermally administering an effective amount of cannabidiol (CBD) to a subject in need thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: September 19, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Donna Gutterman, Terri Sebree
  • METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GEL
    Publication number: 20240189255
    Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.
    Type: Application
    Filed: June 13, 2023
    Publication date: June 13, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Nancy Tich, John Messenheimer, Donna Gutterman, Daniel Clauw, Ted Smith, James Griesser